FDA Approves Portrazza for Advanced Squamous NSCLC

Share this content:
FDA Approves Portrazza for Advanced Squamous NSCLC
FDA Approves Portrazza for Advanced Squamous NSCLC

WEDNESDAY, Nov. 25, 2015 (HealthDay News) -- Portrazza (necitumumab), in combination with two other chemotherapy drugs, has been approved by the U.S. Food and Drug Administration to treat advanced squamous non-small-cell lung cancer (NSCLC), the agency said Tuesday in a news release.

Portrazza, approved for patients who haven't had a previous therapy for squamous NSCLC, is designed to block activity of the epidermal growth factor receptor protein, the agency explained.

The drug was evaluated in combination with two other drugs, gemcitabine and cisplatin. Those who took the three-drug combination lived for an average of 11.5 months, compared to 9.9 months among those who took the other two drugs without Portrazza.

Portrazza's most common side effects included skin rash and hypomagnesemia. The drug's label includes a boxed warning that the latter can cause potential fatal complications, including seizures and irregular heartbeat, the FDA said.

Portrazza is marketed by Indianapolis-based Eli Lilly.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »